Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daclizumab for Active Uveitis
NCT00070759Phase 2Completed
- Sponsor
- National Eye Institute
- Start
- Oct 2003
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daclizumab in intermediate uveitis (IU) and posterior uveitis, sponsored by National Eye Institute. Primary endpoint: Resolution of active disease defined as the reduction of vitreous haze by at least 2 steps at 21 days. Started Oct 2003; status: completed.
02
Drugs
daclizumab
03
Conditions
intermediate uveitis (IU)posterior uveitis
Beyond the preview
Go deeper on NCT00070759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00070759.